TuHURA Biosciences, Inc. Price & Performance (HURA)

TuHURA Biosciences' stock reached a 52-week low of $2, reflecting a 67.14% drop over the past year. Despite this decline, analysts maintain price targets between $9.25 and $15.00. The company is also pursuing a Phase 3 trial for its IFx-2.0 immune response candidate, signaling continued focus on cancer immunotherapy.12

HC Wainwright analysts predict TuHURA Biosciences will post a loss of $0.20 per share in Q2 2025 but maintain a "Buy" rating with a $13.00 price target. Other analysts have also issued positive ratings, underscoring confidence in the company’s immunotherapy advancements despite recent stock volatility.34

TuHURA Biosciences' stock rose 17.4% to $2.46 in after-market trading on Wednesday. This rebound comes after hitting a 52-week low earlier in the week. The company, valued at $104 million, continues to emphasize its Phase 3 immunotherapy trials and strategic developments to address market challenges.25